Catherine P M Hayward Selected Research

Quebec platelet disorder

12/2020	Thrombin generation abnormalities in Quebec platelet disorder.
12/2020	Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts.
1/2017	The duplication mutation of Quebec platelet disorder dysregulates PLAU, but not C10orf55, selectively increasing production of normal PLAU transcripts by megakaryocytes but not granulocytes.
9/2011	Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment.
2/2010	Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene.
2/2009	Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes.
2/2009	Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation.
7/2004	Bleeding risks associated with inheritance of the Quebec platelet disorder.
8/2003	Intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Catherine P M Hayward Research Topics

Disease

18	Hemorrhage 06/2023 - 08/2003
9	Quebec platelet disorder 12/2020 - 08/2003
3	Thrombosis (Thrombus) 07/2022 - 05/2010
3	Thrombocytopenia (Thrombopenia) 07/2022 - 10/2004
1	von Willebrand Diseases (von Willebrand's Disease) 12/2023
1	Congenital Disorders of Glycosylation 06/2023
1	Scott Syndrome 09/2022
1	Venous Thromboembolism 07/2022
1	Hemophilia A (Haemophilia) 07/2022
1	Thromboinflammation 07/2022
1	Thrombophilia 01/2021
1	Wounds and Injuries (Trauma) 01/2021
1	Fibrinolytic Defect 12/2020
1	Factor XIII Deficiency 03/2014
1	Epistaxis (Nosebleed) 03/2009
1	Menorrhagia 03/2009
1	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 12/2008
1	Type 2 von Willebrand Disease 07/2008
1	Bernard-Soulier Syndrome (Giant Platelet Syndrome) 07/2008
1	Hemolytic-Uremic Syndrome 12/2004
1	Chronic Kidney Failure (Chronic Renal Failure) 12/2004
1	Thrombotic Thrombocytopenic Purpura 12/2004
1	Glycogen Storage Disease Type VI (Glycogenosis Type VI) 12/2004
1	Purpura 07/2004
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 07/2004

Drug/Important Bio-Agent (IBA)

9	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 12/2020 - 08/2003
7	Plasminogen Activators (Plasminogen Activator)IBA 12/2020 - 03/2008
5	Proteins (Proteins, Gene)FDA Link 06/2023 - 08/2003
3	Blood Coagulation Factors (Coagulation Factor)IBA 06/2023 - 05/2012
3	Thrombin FDA Link 09/2022 - 12/2020
3	Hemostatics (Antihemorrhagics)IBA 03/2009 - 07/2004
2	RistocetinIBA 12/2023 - 07/2008
2	lipoprotein-associated coagulation inhibitor (TFPI)IBA 06/2023 - 12/2020
2	multimerinIBA 01/2021 - 05/2010
2	Fibrinolysin FDA Link 12/2020 - 02/2009
2	Fibrinogen (Factor I)FDA Link 10/2012 - 12/2008
2	von Willebrand FactorIBA 05/2012 - 12/2004
2	Heparin (Liquaemin)FDA LinkGeneric 12/2007 - 10/2004
1	Vitamin K FDA Link 06/2023
1	AnticoagulantsIBA 06/2023
1	ThrombomodulinIBA 06/2023
1	AnoctaminsIBA 09/2022
1	CalciumIBA 09/2022
1	Phospholipids (Phosphatides)FDA LinkGeneric 09/2022
1	VaccinesIBA 07/2022
1	A-factor (Streptomyces)IBA 01/2021
1	ferric chlorideIBA 01/2021
1	Fibrillar CollagensIBA 01/2021
1	Factor V (Coagulation Factor V)IBA 12/2020
1	ORALIT (ORS)IBA 07/2020
1	CollagenIBA 07/2020
1	Factor XIII (Coagulation Factor XIII)IBA 03/2014
1	alpha-SynucleinIBA 05/2010
1	EnzymesIBA 03/2008
1	ADAMTS13 ProteinIBA 12/2004
1	thiamine triphosphorate (TTP)IBA 12/2004
1	Abciximab (ReoPro)FDA Link 10/2004
1	AntibodiesIBA 07/2004
1	Inosine Triphosphate (ITP)IBA 07/2004

Therapy/Procedure

4	Therapeutics 12/2020 - 12/2004